As COVID-19 surged across the US starting in 2020, so too did the use of repurposed medications such as hydroxychloroquine and ivermectin to treat COVID-19 infections. Use of these medications ...

Certain antiviral and mAb therapies were shown to lower mortality and hospitalization rates in those infected with SARS-CoV-2 Omicron variants.

The Food and Drug Administration (FDA) updated its emergency use authorization (EUA) for Paxlovid (nirmatrelvir/ritonavir) in 2022. This change has allowed people who ...

Study: Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study.

Case series suggests longer nirmatrelvir/ritonavir treatments may benefit some individuals with long COVID, highlighting the need for further research into optimal usage. Study: Impact of extended ...